Evidence map›Paper›PMID 39677294›Full record

ArticleJournal of inflammation research2024

A Targeted Proteomics Approach Reveals a Serum Protein Signature as a Diagnostic Biomarker for Colorectal Cancer.

Yu Wan, Wenfeng Luo, Xiaoyu Song, Ying Zhao, Zeping Han, Jian Shen, Fangmei Xie, Yuguang Li, Jinhua He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu Wan *Gastroenterology Department, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Wenfeng Luo *Central Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Xiaoyu Song *Central Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Ying ZhaoCentral Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Zeping HanCentral Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Jian ShenCentral Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Fangmei XieCentral Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.
Yuguang LiPanyu Maternal and Children Healthcare Hospital (Hexian Memorial Medical Hospital of Panyu District), Guangzhou, Guangdong, 511400, People's Republic of China.
Jinhua HeCentral Laboratory, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511400, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Circulating proteins secreted by tumors are an important source of cancer biomarkers. This study aims to investigate the changes in the content of tumor immune-related circulating proteins in peripheral blood from patients with colorectal cancer (CRC). Methods: Olink's proximity extension assay was used to detect the levels of 92 tumor immune-related circulating proteins in peripheral blood from CRC patients. An enzyme-linked immunosorbent assay was performed to detect the levels of six proteins. Elastic network regression was used to establish the model, and the performance of the model was verified by multiple iterations of cross-validation. Results: The best serum protein signature that was composed of six proteins (IL7, CXCL12, IL10, IL15, CXCL1, and MCP-3) was selected. The area under the curve value of this signature was 0.9924 in the training set and 0.8992 in the total set. IL7 and IL15 levels were significantly higher in the ≥4 cm tumor volume group than in the <4 cm tumor volume group ( Conclusion: The best serum protein signature model (IL7, CXCL12, IL10, IL15, CXCL1, and MCP-3) was able to distinguish CRC patients from healthy controls. These proteins were also involved in the occurrence and development of CRC.

Indexed as

circulating proteincolorectal cancerimmunology-oncology

Identifiers

PMID39677294
PMCPMC11645893

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.